Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia. Show more

3350 Riverwood Parkway SE, Atlanta, GA, 30339, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

218.3M

52 Wk Range

$1.33 - $2.89

Previous Close

$1.80

Open

$1.83

Volume

2,920,259

Day Range

$1.80 - $2.00

Enterprise Value

34.58M

Cash

77.32M

Avg Qtr Burn

-10.59M

Insider Ownership

8.01%

Institutional Own.

87.10%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IkT-001Pro Details Cancer, Hematologic malignancies, Gastric cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IkT-001 Details Pulmonary Arterial Hypertension (PAH)	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Risvodetinib (IkT-148009) Details Neurodegenerative disease, Parkinson's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.